Christina Ip-Toma

Director of Scientific Programs at MIB Agents Osteosarcoma Alliance. Mom of OsteoAngel Dylan.

[R. Lor Randall @RLRandallMD]

Highly relevant, impactful paper. Grateful to ⁦@COGorg⁩ ⁦@AgentsMIB⁩ ⁦@OSInstitute⁩ ⁦@OsteosarcomaNow⁩ ⁦@the_osproject⁩ ⁦@aoa1887⁩ ⁦@AAOS1⁩⁩ ⁦@UCDavisHealth⁩ ⁦@UCDavisOrtho⁩ ⁦@UCD_Cancer⁩ https://t.co/c0WxI2IL41

[Christina Ip-Toma @c_iptoma]

@sarcomapatients Thank you Sarcoma Patient Advocacy Global Network for organizing a tremendous conference to bring us all together and for the travel award. It was an honor to attend, connect with and learn from passionate leaders in the global sarcoma community. #SPAGN2024

[Osteosarcoma Now @OsteosarcomaNow]

🤔 What surgical treatments are available for osteosarcoma that has spread to the lungs? And are they effective?

Our new blog takes a look at a study that aims to answer these questions.

Read the blog: https://t.co/VA2qWSS4ic

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Last month we visited Dr. Robert Canter and the talented sarcoma team at the UC Davis Comprehensive Cancer Center to get an update on his MIB OutSmarting funded work on NK cell therapy for osteosarcoma. Grateful to our MIB Agents Family Funds!

#MIBAgents #MakeItBetter

[Osteosarcoma Now @OsteosarcomaNow]

Today is World Cancer Day. You can access the latest clinicial trials for osteosarcoma by visiting ONTEX https://t.co/iSkwh93PdV #worldcancerday #sarcoma #clinicialtrials #cancer rare disease #raredisease

[Osteosarcoma Now @OsteosarcomaNow]

Happy one year anniversary to our ONTEX clinicial trial database🥳 Thank you to everyone who has supported us in launching and advertising this vital resource. To find out more visit https://t.co/pnuCX1UaWd

[Kyle Satoshi Okimoto @OkimotoKyle]

Each of us have an untapped renewable energy source that can change the world.

Adverse life events create massive energy. Its grip usually bolts us down - fearful, helpless, defeated.

I spent 3 hours yesterday with a unicorn - someone who has flipped the power of adversity to do good - Ann Graham, founder of a non-profit focused on pediatric cancer.

Here's why she is the rarest of the unicorns:

In 2010, Ann was diagnosed with osteosarcoma (OS)

Only 1000 cases of OS occur every year in the US.

It's nearly always found in people under 20. Ann was in her 40s and training for a marathon when she encountered unusual pain. Because OS is a kids' cancer, Ann was treated on the pediatric floor of her NYC hospital.

She discovered that OS treatment had not evolved in decades.

After her treatment, Ann began helping others with OS

Her compassion drove her to create "missions" for fellow patients, including fun experiences and inspirational support.

She worked to build awareness for pediatric cancers on Capitol Hill. She founded a new non-profit - @AgentsMIB (Make It Better Agents) - focused on osteosarcoma.

Many rare cancers like OS are "orphan diseases." Research is more scarce for such diseases because their scarcity make them less financially lucrative.

She has since continued to expand MIB Agents' impact

• Developing guides to help families navigate treatment
• Increasing pediatric cancer support in DC
• Starting a annual conference bringing together medical professionals, pharma companies, patients and their families
• Funding OS research directly through grants

How does she accomplish this? By harnessing her own experience

• A mom
• An OS patient
• A child of Hawaii
• Years of experience and connections in the hospitality industry

All of us encounter adversity, but how we respond is what matters

I met Ann for the first time less than a year ago.

But are deeply connected - born in the same year. Runners. Grew up in Hawaii. Our lives upended by osteosarcoma.

Ann both inspires and challenges me.

When I encounter adversity, what will I do to make this world better? What will you do?

[Tullia Bruno, PhD @BcellBruno]

If anyone is wondering what I want for Christmas. #cytometry #immunology

[Michael Kinnaman, MD MS @MDKinnz]

My Mona Lisa is out in @CR_AACR!

Many thanks to @ciacobu for taking a chance on me and being an incredible mentor along the way!

Also this work couldn’t have been without the foundational support of @RallyFoundation @hopeonwheels @quadwfoundation @ConquerCancerFd - 🙏🙏

[Christina Ip-Toma @c_iptoma]

Another great #CTOS2023! Thrilled to see @janeway_MD give the Herman Suit Lecture. She is moving pediatric sarcoma research ahead and in Dublin, that is commemorated with your face on the head of a Guinness. #makeitbetter @agentsMIB @ctosociety

[Christina Ip-Toma @c_iptoma]

@janeway_MD @UNM @CherylWillmanMD @JanewayLab @count_me_in @PECGSnetwork @broadinstitute Honored to attend the 2023 PE-CGS Meeting in beautiful Albuquerque as a member of the Count Me In Stakeholder Advisory Group. Learning so much and always inspiring to see collaboration in the scientific community and the dedication to patient perspectives and participation.

[Katie Janeway @janeway_MD]

It is the anniversary of our patient partnered osteosarcoma project — https://t.co/cCaK0hGp7i — creating a clinico-genomic database for the research community to drive discovery. Patients enroll online. Consider referring your patients during #childhoodcancerawareness month

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

We are pleased to welcome Dr. Damon Reed as the inaugural Head of the Division of Pediatric Solid Tumors and as Chief of the Pediatric Sarcoma Service at MSK. His research focuses on characterizing the mechanisms of therapeutic resistance.

[Christina Ip-Toma @c_iptoma]

@MSKCancerCenter Congrats!!

[Christina Ip-Toma @c_iptoma]

@Majzner_Lab @DanaFarber @DFBC_PedCare Congrats!!! 👏👏👏

[Osteosarcoma Now @OsteosarcomaNow]

Thanks to funding from @BardoFoundation we attended the FACTOR conference which highlighted the current research into osteosarcoma.

In today's blog, we discuss key topics from the conference such as treating primary cancer & targeting the immune system ➡️https://t.co/tZMbtFf3Mi

[Osteosarcoma Now @OsteosarcomaNow]

Tomorrow our Osteosarcoma Now Newsletter goes out!

Our newsletter is published every 3 months. Each issue will discuss current #osteosarcoma research and showcase the work of sarcoma charities across the world. @CureSarcoma.

Sign up now! 👉https://t.co/r8AlZWfpdo

[Osteosarcoma Now @OsteosarcomaNow]

Finishing a great Biomarker session #FACTOR23 asking how we can combine #osteosarcoma data to accelerate research. @AgentsMIB

[Christina Ip-Toma @c_iptoma]

Celebrating collaboration between the patient and scientific communities at @AgentsMIB FACTOR 2023! Thank you to the Grilo family for funding an #OutSmartingOsteosarcoma grant for @SamVolchenboum at the @UofC for his work on a data commons for bone cancer #BecauseOfAnnaleigh

[Christina Ip-Toma @c_iptoma]

So jazzed about collaboration and connections at our MIBAgents FACTOR 2023 conference! Thanks for attending and Making It Better with us Jazzmin Huber from @OsteosarcomaNow and Jasmine Smith, MD from @StJude